Melatonin receptor agonist
|Melatonin receptor agonist|
|Use||Sleep disorders, depression, etc.|
|Biological target||Melatonin receptor|
Melatonin receptor agonists are analogues of melatonin that bind to and activate the melatonin receptor. Agonists of the melatonin receptor have a number of therapeutic applications including treatment of sleep disorders and depression. The discovery and development of melatonin receptor agonists was motivated by the need for more potent analogues than melatonin, with better pharmacokinetics and longer half-life. Melatonin receptor agonists are analogues of melatonin and were developed with the melatonin structure as a model.
The melatonin receptors are G protein-coupled receptors and are expressed in various tissues of the body. There are two subtypes of the receptor in humans, melatonin receptor 1 (MT1) and melatonin receptor 2 (MT2). Melatonin and melatonin receptor agonists, on market or in clinical trials, all bind to and activate both receptor types. The binding of the agonists to the receptors has been investigated for over two decades or since 1986. It is somewhat known, but still not fully understood. When melatonin receptor agonists bind to and activate their receptors it causes numerous physiological processes.
In 1917 McCord and Allen discovered melatonin itself. Just over 40 years later, in 1958, Aaron B. Lerner and his colleagues isolated the substance N-acetyl-5-methoxytryptamine and named it melatonin. High-affinity melatonin binding sites were pharmacologically characterized in the bovine brain in 1979. The first melatonergic receptor was cloned from melanophores of Xenopus laevis in the 1990s. In 1994 the melatonin receptors were characterized and cloned in the human being. There has been a constant growth in the field of melatonin and melatonin analogues since the 1980s. In 2005 Ramelteon (Rozerem®) was the first melatonin agonist to be approved in the United States (US), indicated for insomnia treatment in adults which is characterized as difficulty with falling asleep. Melatonin in the form of prolonged release (trade name Circadin®) was approved in 2007 in Europe (EU) for use as a short-term treatment, in patients 55 years or older, for primary insomnia (poor quality of sleep). Products containing melatonin are available as a dietary supplement in the United States and Canada. In 2009 agomelatine (Valdoxan®, Melitor®, Thymanax®) was also approved in Europe and is indicated for the treatment of major depressive disorder in adults. Tasimelteon completed the phase III clinical trial in the United States for primary insomnia in 2010. The Food and Drug Administration (FDA) granted tasimelteon orphan drug designation status for blind individuals without light perception with non-24-hour sleep–wake disorder in January the same year. TIK-301 (PD-6735, LY-156,735) has been in phase II clinical trial in the United States since 2002. The FDA granted TIK-301 orphan drug designation in May 2004, to use as a treatment for circadian rhythm sleep disorder in blind individuals without light perception and individuals with tardive dyskinesia.
In humans there are two subtypes of melatonin receptors, MT1 and MT2. They are G protein-coupled receptors and are expressed in various tissues of the body, together or singly. MT1 receptors are expressed in many regions of the central nervous system (CNS): suprachiasmatic nucleus (SCN) of the hypothalamus, hippocampus, substantia nigra, cerebellum, central dopaminergic pathways, ventral tegmental area and nucleus accumbens. MT1 is also expressed in the retina, ovary, testis, mammary gland, coronary circulation and aorta, gallbladder, liver, kidney, skin and the immune system. MT2 receptors are expressed mainly in the CNS, also in the lung, cardiac, coronary and aortic tissue, myometrium and granulosa cells, immune cells, duodenum and adipocytes.
Mechanism of action
The binding of melatonin to melatonin receptors activates a few signaling pathways. MT1 receptor activation inhibits the adenylyl cyclase and its inhibition causes a rippling effect of non activation; starting with decreasing formation of cyclic adenosine monophosphate (cAMP), and then progressing to less protein kinase A (PKA) activity, which in turn hinders the phosphorylation of cAMP responsive element-binding protein (CREB binding protein) into P-CREB. MT1 receptors also activate phospholipase C (PLC), affect ion channels and regulate ion flux inside the cell. The binding of melatonin to MT2 receptors inhibits adenylyl cyclase which decreases the formation of cAMP. As well it hinders guanylyl cyclase and therefore the forming of cyclic guanosine monophosphate (cGMP). Binding to MT2 receptors probably affects PLC which increases protein kinase C (PKC) activity. Activation of the receptor can lead to ion flux inside the cell.
When melatonin receptor agonists activate their receptors it causes numerous physiological processes. MT1 and MT2 receptors may be a target for the treatment of circadian and non circadian sleep disorders because of their differences in pharmacology and function within the SCN. The SCN is responsible for maintaining the 24 hour cycle which regulates many different body functions ranging from sleep to immune functions. Melatonin receptors have been identified in the cardiovascular system. Number of animal studies point to a dual role of melatonin in the vasculature. Activation of MT1 receptors mediates vasoconstriction and the activation of MT2 receptors mediates vasodilation. Melatonin is involved in regulating immune responses in both human and animals through activation of both MT1 and MT2 receptors. MT1 and MT2 receptors are widespread in the eye and are involved in regulating aqueous humor secretion, which is important for glaucoma, and in phototransduction. This is not a complete list since many of the possible processes need further confirmation.
Drug design and development
Receptors and the structure of melatonin are known. Therefore researchers started to investigate modulations of the core structure to develop better agonists than melatonin; more potent, with better pharmacokinetics and longer half-life. TIK-301 (figure 1) is an agonist of the early classes. It is very similar to melatonin and has made it to clinical trials. This led to further researches on the molecule, mainly substitution of the aromatic ring. Various modulations showed promising activity, specially the naphthalene ring which is present in agomelatine (figure 1). Other ring systems have also showed melatonin agonist activity. Amongst them are indane which is present in ramelteon (figure 1) and the ring system of tasimelteon (figure 1).
Structure-activity relationship (SAR)
The general structure of melatonin is the indole ring with methoxy group in position 5 (5-methoxy group) and acylaminoethyl side-chain in position 3. The two side-chains are important for binding to and activating the receptors. The indole ring has been evaluated at all positions by the effect of substitutions as seen in figure 1. Each position is further explained below:
|1||R1||Possible to substitute with small groups like methyl without little changes in binding affinity. Bulky groups lower binding affinity and intrinsic activity.|
|2||R2||Molecules like iodine (I) and bromine (Br) and phenyl groups lead to agonists with higher binding affinity or approximately ten-fold.|
|3||R3||The acylaminoethyl side-chain is important, as mentioned before. In this position it is possible to control agonist and antagonist activity.|
|4||R4||Often involved in ring closure in melatonin agonists, although this position has been poorly investigated.|
|5||R5||The methoxy group is important, as mentioned before. Substitution with halogens, such as chlorine (Cl) and bromine (Br) has shown lower binding affinity. Moving the methoxy group to other positions on the indole ring, e.g. 4, 6 or 7, leads to lower binding affinity.|
|6||R6||Substitution leads to lower binding affinity, but this position is important for the pharmacokinetics. The main metabolite in vivo is 6-hydroxymelatonin.|
|7||R7||Introduction of groups at this position generally leads to lower binding affinity.|
|β||Rβ||Possible to substitute with small groups like methyl without little changes in binding affinity. Bulkier groups lower binding affinity.|
Binding and pharmacophore
2-Iodomelatonin was synthesized in 1986 and its radioligand, 2-[125I]-melatonin, has been useful in finding cellular targets of melatonin. Though the melatonin receptor wasn’t characterized and cloned in the human being until 1994 it was possible to start carrying out binding studies in various tissues before that time. As mentioned in the structure-activity relationship chapter above, certain groups are important for the activity. The most important groups are the 5-methoxy group and the acylaminoethyl side-chain, because they bind to and activate the receptors. The –NH group of the indole ring is not important for binding and activation. Therefore it is possible to replace it with other aromatic ring systems. The aromatic ring and the ethyl side-chain hold the correct distance between those two groups. The correct distance is the key to good binding and more important than what type of aromatic ring system the analogue contains. Therefore it is possible to use different ring systems in melatonin receptor analogues, if the distance is right.
The melatonin receptors consist of proteins around 40 kDa each. The MT1 receptor encodes 350 amino acids and the MT2 encodes 362 amino acids. The binding of melatonin and its analogues to the receptors is not fully known. The binding space for melatonin and analogues on the MT1 receptor is smaller than on the MT2. Investigations usually focus on two binding pockets, for the two side-chains. The binding pocket of the 5-methoxy group is more investigated than the other pocket. Researchers agree that the oxygen in the group binds to histidine (His) residues in transmembrane 5 (TM5) domain of the receptor with a hydrogen bond; His195 in MT1 and His208 in MT2. Another amino acid, valine 192 (Val), also participates in the binding of the 5-methoxy group by binding to the methyl portion of the group.
The binding of the N-acetyl group is more complex and less known. The important amino acids in the binding pocket for this group differ between the two receptors. Serines, Ser110 and Ser114, in the TM3 domain seem to be important for binding to the MT1 receptor. However, aspargine 175 (Asn) in the TM4 domain is likely to be important for the MT2 receptor. The aromatic ring system in melatonin and analogues most likely contributes some binding affinity by binding to aromatic rings of the amino acids phenylalanine (Phe) and tryptophan (Trp) in the receptor. The bonds that form are van der Waals interactions. The N-acetyl binding and binding pocket, binding of the ring system and important domains are somewhat known and need further investigation.
There are three melatonin agonists on the market today (February 2014); ramelteon (Rozerem®), agomelatine (Valdoxan®, Melitor®, Thymanax®) and tasimelteon (Hetlioz®). Ramelteon was developed by Takeda Pharmaceutical Company and approved in the United States 2005. Agomelatine was developed by the pharmaceutical company Servier and approved in Europe 2009. Tasimelteon was developed by Vanda Pharmaceuticals and completed the phase III trial in 2010. It was approved by the FDA on January 31, 2014 for the treatment of non-24-hour sleep–wake disorder in totally blind individuals.
One melatonin agonist have received orphan drug designation and is going through clinical trials in the United States: TIK-301. Originally TIK-301 was developed by Eli Lilly and Company and called LY-156,735, it wasn't until July 2007 that Tikvah Pharmaceuticals took over the development and named it TIK-301. It is now in phase II trials and has been since 2002. In July 2010 in Europe, prolonged-release melatonin (Circadin®, Neurim Pharmaceuticals) was approved for use for 13 weeks for insomnia patients over 55 years old. Additionally, Neurim Pharmaceuticals reported the results of a positive phase II trial of its investigational compound piromelatine (Neu-P11) in February 2013.
|Binding affinity||—||MT1: Ki = 0.014 nM
MT2: Ki = 0.045 nM
|MT1: Ki = 0.062 nM
MT2: Ki = 0.268 nM
5-HT2C: IC50 = 270 nM*
|MT1: Ki = 0.35 nM
MT2: Ki = 0.17 nM
|MT1: Ki = 0.081nM
MT2: Ki = 0.042 nM
|Bioavailability||15%||< 2%||< 5%||not determined in humans||—|
3.5–4 h (terminal)
|1–2 h||1–2 h||0.9–1.7 h
0.8–5.9 h (terminal)
|Volume of distribution||—||73.6 L||35 L||56–126 L||—|
|Company||Neurim Pharmaceuticals||Takeda Pharmaceutical Company||Servier||Vanda Pharmaceuticals||Tikvah Pharmaceuticals|
- TIK-301 (LY-156,735, PD-6735)
- Rivara, S., Mor, M., Bedini, A., Spadoni, G., Tarzia, G. (2008). "Melatonin Receptor Agonists: SAR and Application to the Treatment of Sleep–Wake Disorders". Current Topics in Medicinal Chemistry 8 (11): 954–968. doi:10.2174/156802608784936719. PMID 18673165.
- Pandi-Perumal, S. R., Trakht, I., Srinivasan, V., Spence, D. W., Maestroni, G. J. M., Zisapel, N., Cardinali, D. P. (2008). "Physiological effects of melatonin: Role of melatonin receptors and signal transduction pathways". Progress in Neurobiology 85 (3): 335–353. doi:10.1016/j.pneurobio.2008.04.001. PMID 18571301.
- Sugden, D., Davidson, K., Hough, K. A., Teh, M. T. (2004). "Melatonin, Melatonin Receptors and Melanophores: A Moving Story". Pigment Cell Research 17 (5): 454–460. doi:10.1111/j.1600-0749.2004.00185.x. PMID 15357831.
- Dubocovich, M. L., Delagrange, P., Krause, D. N., Sugden, D., Cardinali, D. P., Olcese, J. (2010). "International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, Classification, and Pharmacology of G Protein-Coupled Melatonin Receptors". Pharmacological Reviews 62 (3): 343–380. doi:10.1124/pr.110.002832. PMC 2964901. PMID 20605968.
- Witt-Enderby, P. A., Bennett, J., Jarzynka, M. J., Firestine, S., Melan, M. A. (2003). "Melatonin receptors and their regulation: biochemical and structural mechanism". Life Sciences 72 (20): 2183–2198. doi:10.1016/S0024-3205(03)00098-5. PMID 12628439.
- de Bodinat, C., Guardiola-Lemaitre, B., Mocaër, E., Renard, P., Muñoz, C., Millan, M. J. (2010). "Agomelatine, the first melatonergic antidepressant: discovery, characterization and development". Natural Reviews Drug Discovery 9 (8): 628–642. doi:10.1038/nrd3140. PMID 20577266.
- Ferguson, S. A., Rajaratnam, S. M. W., Dawson, D. (2010). "Melatonin agonists and insomnia". Expert Reviews 10 (2): 305–318. doi:10.1586/ern.10.1. PMID 20136385.
- Rajaratnam, S. M. W., Cohen, D. A., Rogers, N. L. (2009). "Melatonin and Melatonin Analogues". Sleep Medicine Clinics 4 (2): 179–193. doi:10.1016/j.jsmc.2009.02.007.
- "Takeda Pharmaceuticals North America, Inc". Tpna.com. Retrieved 2012-02-10.
- "Experts compared, sleep tips, jet lag, seasonal affective disorder". Melatonin.com. Retrieved 2012-02-10.
- "VANDA Pharmaceuticals:". Vandapharma.com. Retrieved 2012-02-10.
- Dubocovich, M. L. (2007). "Melatonin receptors: Role on sleep and circadian rhythm regulation". Sleep Medicine 8: 34–42. doi:10.1016/j.sleep.2007.10.007. PMID 18032103.
- Food and Drug Administration (January 31, 2014). "FDA NEWS RELEASE: FDA approves Hetlioz: first treatment for non-24 hour sleep-wake disorder in blind individuals". FDA.
- "Future Treatments for Depression, Anxiety, Sleep Disorders, Psychosis, and ADHD". Neurotransmitter.net. 2011-06-17. Retrieved 2012-02-10.
- "Circadin® approved in the EU for treatment of Primary Insomnia in patients aged 55 or over for up to 3 months | Neurim Pharmaceuticals". Neurim.com. 2011-11-21. Retrieved 2012-02-10.
- "Prolonged-Release Melatonin | Circadin®". Circadin.com. 2012-02-01. Retrieved 2012-02-10.
- "Servier". Valdoxan.com. Retrieved 2012-02-10.
- "Hetlioz™ (tasimelteon) capsules 20 mg, Prescribing Information", Vanda Pharmaceuticals Inc., 2014. Revised January 2014. 
- "Tasimelteon Advisory Committee Meeting Briefing Materials", Vanda Pharmaceuticals Inc., November 2013.